Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma
The Journal of Allergy and Clinical Immunology: In Practice · 2024
DOI: 10.1016/j.jaip.2024.02.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Brian Lipworth und 3 weiteren Autor:innen. Beteiligte Einrichtung: Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom. Electronic address: b…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Overuse of reliever as short-acting beta-agonist and associated underuse of controller as inhaled corticosteroid (ICS) administered via separate inhalers results in worse asthma outcomes. Such discordance can be obviated by combining both controller and reliever in the same inhaler. So-called anti-inflammatory reliever (AIR) therapy comprises the use of a single inhaler containing an ICS such as budesonide (BUD) in conjunction with a reliever as either albuterol (ALB) or formoterol (FORM), to be used on demand, with variable dosing driven by asthma symptoms in a flexible patient-centered regimen. Global guidelines now support the use of BUD-ALB as AIR therapy to reduce exacerbations, either on its own in mild asthma or in conjunction with fixed-dose maintenance ICS-long-acting beta-agonist in moderate to severe asthma. Using BUD-FORM on its own allows patients to seamlessly move in an intuitive flexible fashion between AIR and maintenance and reliever therapy, by stepping up and down the dosing escalator across a spectrum of asthma severities. Head-to-head clinical studies are indicated to compare BUD-FORM versus BUD-ALB as AIR in mild asthma, and also BUD-FORM as maintenance and reliever therapy versus BUD-ALB as AIR plus maintenance ICS-long-acting beta-agonist in moderate to severe asthma. Patients should be encouraged to make an informed decision in conjunction with their health care professional regarding the best therapeutic option tailored to their individual needs, which in turn is likely to result in long-term compliance and associated optimal asthma control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom. Electronic address: b.j.lipworth@dundee.ac.uk.
- Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.
Zitieren
APA
Lipworth, B., Kuo, C. R., Stewart, K., & Chan, R. (2024). Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.02.003
Vancouver
Lipworth B, Kuo CR, Stewart K, Chan R. Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2024.02.003
BibTeX
@article{Lipworth2024,
author = {Lipworth, Brian and Kuo, Chris RuiWen and Stewart, Kirsten and Chan, Rory},
title = {Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2024},
doi = {10.1016/j.jaip.2024.02.003}
}
EUVIMED